ADDRENEX PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.addrenex.com
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Phase 2
1 (33.3%)A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00779181
CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
Phase 3
Completed
- Conditions
- ADHD
- Interventions
- Drug: CLONICEL (clonidine HCl sustained release)Drug: Placebo
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00641329
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT00556959
News
No news found